Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ
Tải xuống
Tuyển tập các báo cáo nghiên cứu về hóa học được đăng trên tạp chí sinh học đề tài : A lifeline to treatment: the role of Indian generic manufacturers in supplying antiretroviral medicines to developing countries | Waning et al. Journal of the International AIDS Society 2010 13 35 http www.jiasociety.Org content 13 1 35 JOURNALOF THE INTERNATIONAL AIDS SOCIETY SHORT REPORT Open Access A lifeline to treatment the role of Indian generic manufacturers in supplying antiretroviral medicines to developing countries Brenda Waning1 2 Ellen Diedrichsen1 Suerie Moon3 Abstract Background Indian manufacturers of generic antiretroviral ARV medicines facilitated the rapid scale up of HIV AIDS treatment in developing countries though provision of low-priced quality-assured medicines. The legal framework in India that facilitated such production however is changing with implementation of the World Trade Organization Agreement on Trade-Related Aspects of Intellectual Property Rights and intellectual property measures being discussed in regional and bilateral free trade agreement negotiations. Reliable quantitative estimates of the Indian role in generic global ARV supply are needed to understand potential impacts of such measures on HIV AIDS treatment in developing countries. Methods We utilized transactional data containing 17 646 donor-funded purchases of ARV tablets made by 115 low- and middle-income countries from 2003 to 2008 to measure market share purchase trends and prices of Indian-produced generic ARVs compared with those of non-Indian generic and brand ARVs. Results Indian generic manufacturers dominate the ARV market accounting for more than 80 of annual purchase volumes. Among paediatric ARV and adult nucleoside and non-nucleoside reverse transcriptase inhibitor markets Indian-produced generics accounted for 91 and 89 of 2008 global purchase volumes respectively. From 2003 to 2008 the number of Indian generic manufactures supplying ARVs increased from four to 10 while the number of Indian-manufactured generic products increased from 14 to 53. Ninety-six of 100 countries purchased Indian generic ARVs in 2008 including high HIV-burden sub-Saharan African countries. Indian-produced
